Search Results - diabetes

12 Results

Sort By:

Compounds that Interfere with the Androgen Receptor Complex

Abstract: Investigators at the National Institutes of Health (NIH) have discovered compounds that have potential as novel anti-androgen therapeutics. The immunophilin protein FKBP52 is part of a protein complex that helps fold the androgen receptor (AR) protein, a target for treating prostate cancer, and enhances its activity. Disruption of the FKPB52-AR...

Published: 4/8/2024 | Inventor(s): Leonard Neckers, Jane Trepel Neckers, Yeong Kim, Aki Iwai, Yangmin Ning, Marc Cox, Johanny Meneses De Leon, Heather Balsiger, Robert Fletterick

Keywords(s): androgen receptor protein, DIABETES, PROSTATE CANCER

Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Endocrinology

Novel Human Insulin Cα-Peptide as an Antagonist for Islet and Brain Amyloidosis

Abstract: Over 32 million Americans are living with Diabetes and newly diagnosed cases of type 1 and type 2 diabetes is increasing. A defining feature of type 2 diabetes mellitus (T2DM) is the accumulation of islet amyloid polypeptide (IAPP) fibrils in pancreatic islets. Such accumulations form amyloid plaques, referred to as islet amyloidosis. Mounting...

Published: 4/8/2024 | Inventor(s): Qing Rong Liu, Min Zhu, Pingbo Zhang, Josephine Egan, Luigi Ferrucci

Keywords(s): Alzheimer’s Disease, Amyloidosis, C-peptide, DIABETES, Egan, insulin, Islet Amyloid Polypeptide, Liu, National Institute on Aging, NIA

Category(s): Collaboration Sought > Licensing, Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Endocrinology

IL7Rα-Specific Antibody for Treating Acute Lymphoblastic Leukemia (ALL)

Abstract: Acute lymphoblastic leukemia (ALL) is the most common cancer in children with approximately 3,250 new cases occurring per year in the United States. About 20% of cases are refractory to current treatment protocols and there is a desperate need for targeted therapies that do not result in adverse side effects such as cognitive impairment. The...

Published: 4/8/2024 | Inventor(s): Scott Durum, Julie Hixon, Wenqing Li, Scotch Walsh, Lila Kashi

Keywords(s): Acute lymphoblastic leukemia (ALL), ANTIBODY, Antibody-Dependent Cellular Cytotoxicity (ADCC), Autoimmunity, CANCER, DIABETES, Durum, Interleukin-7 receptor-α (IL-7Rα), Multiple sclerosis, personalized medicine, Targeted therapy, THERAPY, TRANSPLANTATION

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Collaboration

Renal Selective Unsaturated Englerin Analogues

Abstract: Englerin A, a natural product, has shown growth-inhibiting activity against renal cancer cell lines. The compound is an agonist of protein kinase C (PCK) theta, which results in cell cytotoxicity, insulin inhibition, and selective activation of viral replication in T cells. Englerin A derivatives are promising treatment strategies for any...

Published: 4/8/2024 | Inventor(s): John Beutler, Tanya Ransom, Antonio Echavarren, Frederic Ratel

Keywords(s): Beutler, DIABETES, HIV, renal cancer, small molecule

Category(s): TherapeuticArea > Endocrinology, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease

Novel Human Islet Amyloid Polypeptides as Alzheimer’s Disease Biomarkers and Inhibitors of Amyloid Formation

Abstract: Over 34 million Americans are living with diabetes. An estimated 6.5 million Americans are living with Alzheimer’s disease (AD) and type 2 diabetes mellites (T2DM). Amyloidosis due to aggregation of amyloid-β is key pathogenic event in AD, whereas aggregation of mature islet amyloid polypeptide (IAPP37) in human islet leads to β-cell dysfunction....

Published: 5/23/2024 | Inventor(s): Qing Rong Liu, Min Zhu, Josephine Egan

Keywords(s): Ad, Age-Associated Disease, Alzheimer’s Disease, Amyloidosis, Amyloids, Biomarkers, DIABETES, IAPP, Islet Amyloid Polypeptide Isoforms, Liu, National Institute on Aging, NIA, PEPTIDYL

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics

Small Interfering RNA Inhibition of Cannabanoid-1 Receptor (CB1R) for Treating Type 2 Diabetes

The invention pertains to the use of glucan encapsulated non-immunostimulatory small interfering RNAs (siRNAs) to treat type-2 diabetes. Endocannabinoids (EC) are lipid signaling molecules that act on the same cannabinoid receptors that recognize and mediate the effects of endo- and phytocannabanoids. EC receptor CB1R activation is implicated in the...

Published: 7/25/2024 | Inventor(s): Tony Jourdan, Michael Czech, Myriam Aouadi, George Kunos

Keywords(s): CB1, DIABETES, GB1AXX, GB1XXX, GBXXXX, GXXXXX, IBXXXX, IXXXXX, Knockdown, MACROPHAGES, RECEPTORS, SELECTIVE, SiRNA-mediated, treatment

Category(s): Collaboration Sought > Licensing, Application > Research Materials, Application > Diagnostics, Application > Therapeutics

Adeno-Associated Virus Gene Therapy for Diabetes and Obesity

This invention is directed to adeno-associated virus (AAV) vector delivery of exendin-4 (Ex-4) to salivary glands as treatment for diabetes and obesity. Ex-4 is a potent and long-acting agonist of the receptor for glucagon-like peptide 1 (GLP-1). Scientists at NIDCR have shown that AAV-mediated delivery of Ex-4 resulted in improved glucose homeostasis...

Published: 7/25/2024 | Inventor(s): Giovanni Di Pasquale, Edward Mannucci, John (Jay) Chiorini

Keywords(s): DIABETES, EPITHELIA, Expression, Fusion, GBXXXX, Gland, IBXXXX, Listed LPM Contreras as of 4/15/2015, NGF/exendin-4, Novel, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Protein, Salivary, treatment

Category(s): Application > Therapeutics

Selective 12-Human Lipoxygenase Inhibitors for the Treatment of Diabetes and Clotting

This invention discloses small molecule inhibitors of human 12-lipoxygenase (12-hLO). 12-lipoxygenase expression, activation, and lipid metabolites have been implicated in type 1 and type 2 diabetes, cardiovascular disease, hypertension, Alzheimer’s, and Parkinson’s disease. The development of 12-hLO inhibitors may be a potent intracellular approach...

Published: 7/25/2024 | Inventor(s): Jerry Nadler, Michael Holinstat, Anton Simeonov, Ajit Jadhav, Theodore Holman, David Maloney

Keywords(s): 12-human, Cardiovascular, CAUSED, Clot, DIABETES, Discovery, Disease, Formation, IA1AXX, IA1XXX, IAXXXX, Inhibitors, IXXXXX, LIPOXYGENASE, Platelet-mediated, Prevention, SELECTIVE, treatment

Category(s): Collaboration Sought > Licensing, Application > Research Materials, TherapeuticArea > Cardiology, Application > Therapeutics, Application > Diagnostics

Conditional V2 Vasopressin Receptor Mutant Mice as a Model to Study X-linked Nephrogenic Diabetes Insipidus (XNDI)

X-linked nephrogenic diabetes insipidus (XNDI) is a severe kidney disease caused by inactivating mutations in the V2 vasopressin receptor (V2R) gene that result in the loss of renal urine-concentrating ability. At present, no specific pharmacological therapy has been developed for XNDI, primarily due to the lack of suitable animal models. This technology...

Published: 7/25/2024 | Inventor(s): Jurgen Wess

Keywords(s): ACXXXX, AXXXXX, Chromosome 7, monosomy, Conditional, Deletion 7, DIABETES, Insipidus, Mice, MUTANT, Nephrogenic, Nephrogenic diabetes insipidus, Novel, RECEPTOR, RXXXXX, STRATEGY, Studied, treatment, V2, VASOPRESSIN, X-LINKED

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Collaboration Sought > Materials Available, Application > Research Materials

Aquaporin 2 Polyclonal Antibodies

Aquaporins, also known as water channels, form pores in cell membranes and selectively transport water in and out of the cell. Aquaporins are involved in regulation of water balance and blood pressure, and thirteen different isoforms have been found in mammals. Aquaporin 2 (AQP2) is located in the collecting duct of the kidney, and is regulated by...

Published: 7/25/2024 | Inventor(s): Mark Knepper

Keywords(s): Anti-Aquaporin, antibodies, ANTIBODY, AQUAPORIN, DIABETES, diabetes insipidus, IDXXXX, IXXXXX, KIDNEY, Nephrogenic diabetes insipidus, polyclonal, polyclonal antibodies, UAXXXX, WATER, water channel

Category(s): Collaboration Sought > Licensing, Collaboration Sought > Materials Available, TherapeuticArea > Rare / Neglected Diseases, Application > Research Materials, Application > Diagnostics, Application > Therapeutics

1 2